Gilead loses oncology leader Riva days into CEO O'Day's new stint
Only a few days into the job, new Gilead CEO Daniel O’Day has a key commercial position to fill. Late Tuesday, the big biotech said Alessandro Riva, M.D., its EVP of oncology, would leave the company. He’ll stay on through the end of the month, at which time he’ll take the helm of Glenmark Pharmaceuticals’… Read More »